850697-56-2

Basic information

• Product Name: 1-Piperidinecarboxylic acid, 4-[(5-fluoro-2-nitrophenyl)amino]-, ethyl ester
• CAS NO: 850697-56-2
• Molecular Formula: C14H18FN3O4
• Molecular Weight: 311.313
• Mol File: 850697-56-2.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 1-Piperidinecarboxylic acid, 4-[(5-fluoro-2-nitrophenyl)amino]-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperidinecarboxylic acid, 4-[(5-fluoro-2-nitrophenyl)amino]-, ethyl ester(850697-56-2)
• EPA Substance Registry System: 1-Piperidinecarboxylic acid, 4-[(5-fluoro-2-nitrophenyl)amino]-, ethyl ester(850697-56-2)

Safety Data

• Hazardous Substances Data: 850697-56-2(Hazardous Substances Data)

Upstream product

• 58859-46-4 ethyl 4-aminopiperidine-1-carboxylate 
• 364-74-9 1,4-difluoro-2-nitrobenzene 
• 446-35-5 2,4-Difluoronitrobenzene 

Downstream Products

• 913195-96-7 ethyl 4-[(2-amino-5-fluorophenyl)amino]-1-piperidinecarboxylate 
• 610323-35-8 6-fluoro-1-(piperidin-4-yl)-1-H-benzo[d]imidazol-2(3H)-on 

Relevant articles and documents

Synthesis and SAR of analogues of the M1 allosteric agonist TBPB. Part I: Exploration of alternative benzyl and privileged structure moieties

This Letter describes the first account of the synthesis and SAR, developed through an iterative analogue library approach, of analogues of the highly selective M1 allosteric agonist TBPB. With slight structural changes, mAChR selectivity was maintained, but the degree of partial M1 agonism varied considerably.

BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR

Compounds of formula (I) and salts and solvates are provided: wherein R6 is selected from hydrogen, halogen, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C3-6cycloalkyl, C3-6cycloalkyl substituted with one or more fluorine atoms, C1-6 alkoxy, C1-6 alkoxy substituted with one or more fluorine atoms, and cyano, and Q is hydrogen or C1-6alkyl. The compounds are M1 agonists and are useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.

Discovery and SAR studies of a novel series of noncovalent cathepsin S inhibitors

A novel series of competitive, reversible cathepsin S (CatS) inhibitors was discovered and optimized. The 4-(2-keto-1-benzimidazolinyl)-piperidin-1-yl moiety was found to be an effective replacement for the 4-arylpiperazin-1-yl group found in our earlier series of CatS inhibitors. This replacement imparted improved PK properties as well as decreased off-target activity. Optimization of the ketobenzimidazole moiety led to the discovery of the lead compound JNJ 10329670, which represents a novel class of selective, noncovalent, reversible, and orally bioavailable inhibitors of cathepsin S.